These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9303217)
1. Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats. Tanaka M; Natori M; Ishimoto H; Miyakoshi K; Miyazaki T; Kobayashi T; Yoshimura Y Biol Neonate; 1997; 72(3):181-6. PubMed ID: 9303217 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model. Garvin PJ; Niehoff ML; Robinson SM; Heisler T; Salinas-Madrigal L; Contis J; Solomon H Transplantation; 1996 May; 61(10):1429-34. PubMed ID: 8633364 [TBL] [Abstract][Full Text] [Related]
3. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats. Gomi T; Ikeda T; Ishimitsu T; Uehara Y Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692 [TBL] [Abstract][Full Text] [Related]
4. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord]. Morimoto K; Ikata T; Tounai T Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of thromboxane A2 activity during warm ischemia of the liver. Shirabe K; Kin S; Shinagawa Y; Chen S; Payne WD; Sugimachi K J Surg Res; 1996 Feb; 61(1):103-7. PubMed ID: 8769950 [TBL] [Abstract][Full Text] [Related]
6. The protective effect of thromboxane A2 synthetase inhibitor against ischemic liver injury. Isozaki H; Okajima K; Hara H; Kobayashi M Surg Today; 1994; 24(5):435-40. PubMed ID: 8054815 [TBL] [Abstract][Full Text] [Related]
7. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H Stroke; 1985; 16(2):241-4. PubMed ID: 3883580 [TBL] [Abstract][Full Text] [Related]
8. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [TBL] [Abstract][Full Text] [Related]
9. The effects of thromboxane A2 synthetase inhibitor (OKY-046) on complete hepatic ischemia in rats with obstructive jaundice. Takahashi T Surg Today; 1996; 26(1):15-20. PubMed ID: 8680115 [TBL] [Abstract][Full Text] [Related]
10. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. Shikano M; Ito T; Ogawa K; Satake T Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562 [TBL] [Abstract][Full Text] [Related]
11. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. Casey LC; Fletcher JR; Zmudka MI; Ramwell PW J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528 [TBL] [Abstract][Full Text] [Related]
12. Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on experimentally induced air embolism in anesthetized dogs. Ishihara Y; Uchida Y; Kitamura S Prostaglandins Leukot Med; 1986 Feb; 21(2):197-206. PubMed ID: 3457388 [TBL] [Abstract][Full Text] [Related]
13. A high plasma prostaglandin to thromboxane ratio protects against renal ischemia. Kaufman RP; Anner H; Kobzik L; Valeri CR; Shepro D; Hechtman HB Surg Gynecol Obstet; 1987 Nov; 165(5):404-9. PubMed ID: 3672299 [TBL] [Abstract][Full Text] [Related]
14. [Experimental study on the pathophysiology of endotoxin shock as analysed by alterations in thromboxane B2 and 6-keto-PGF1 alpha levels]. Baba H Nihon Geka Gakkai Zasshi; 1988 Jan; 89(1):6-20. PubMed ID: 3283521 [TBL] [Abstract][Full Text] [Related]
15. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S Nephron; 1990; 56(3):297-305. PubMed ID: 2077412 [TBL] [Abstract][Full Text] [Related]